View All Documents & Correspondence
Antibody Drug Complex Containing Toll Like Receptor 7/8 Dual Agonist Compound
Abstract: The present invention addresses the problem of developing an antibody-drug complex containing a TLR7/8 dual agonist compound or a salt thereof to provide a pharmaceutical composition used for the prevention or treatment of various types of cancer. The present inventors have discovered a compound having a TLR7/8 dual agonistic activity or a salt thereof, and have studied on an antibody-drug complex that can be used as an active ingredient for a pharmaceutical composition for the prevention or treatment of various types of cancer. As a result, it is found that the antibody-drug complex of the present invention or a salt thereof has a TNF-a- and INF-?-producing effect and an in vivo anti-tumor effect and can be used for the prevention or treatment of cancer. Furthermore, an anti-CLDN6 antibody is also discovered, which is used for the antibody-drug complex of the present invention or a salt thereof. The antibody-drug complex containing a TLR7/8 dual agonist compound according to the present invention or a salt thereof, and a compound represented by formula (II) according to the present invention or a salt thereof have a TNF-a- and INF-?-producing effect and an in vivo anti-tumor effect and are expected as a prophylactic or therapeutic agent for cancer.
Notices, Deadlines & Correspondence
Patent Information
Applicants
ASTELLAS PHARMA INC.
Inventors
1. AKAIWA, Michinori
2. SEKI, Yohei
3. WANG, Yinghua
4. MIGUELEZ, Javier Ramos
5. OHNUKI, Kei
6. KAMIKUBO, Takashi
7. ASANO, Toru
8. KAMIKAWA, Akio
9. CHAEN, Takashi
10. HOSHI, Rika
11. SOGA, Shinji
12. KWON, Chulwon
Specification
Documents
Application Documents
| # | Name | Date |
|---|---|---|
| 1 | 202547030230-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [28-03-2025(online)].pdf | 2025-03-28 |
| 2 | 202547030230-STATEMENT OF UNDERTAKING (FORM 3) [28-03-2025(online)].pdf | 2025-03-28 |
| 4 | 202547030230-Sequence Listing in PDF [28-03-2025(online)].pdf | 2025-03-28 |
| 5 | 202547030230-REQUEST FOR EXAMINATION (FORM-18) [28-03-2025(online)].pdf | 2025-03-28 |
| 6 | 202547030230-PRIORITY DOCUMENTS [28-03-2025(online)].pdf | 2025-03-28 |
| 7 | 202547030230-FORM 18 [28-03-2025(online)].pdf | 2025-03-28 |
| 8 | 202547030230-FORM 1 [28-03-2025(online)].pdf | 2025-03-28 |
| 9 | 202547030230-DRAWINGS [28-03-2025(online)].pdf | 2025-03-28 |
| 10 | 202547030230-DECLARATION OF INVENTORSHIP (FORM 5) [28-03-2025(online)].pdf | 2025-03-28 |
| 11 | 202547030230-COMPLETE SPECIFICATION [28-03-2025(online)].pdf | 2025-03-28 |
| 12 | 202547030230-CLAIMS UNDER RULE 1 (PROVISIO) OF RULE 20 [28-03-2025(online)].pdf | 2025-03-28 |
| 13 | 202547030230-FORM-26 [01-04-2025(online)].pdf | 2025-04-01 |
| 14 | 202547030230-FORM 3 [29-04-2025(online)].pdf | 2025-04-29 |
| 15 | 202547030230-Proof of Right [11-09-2025(online)].pdf | 2025-09-11 |
| 16 | 202547030230-FORM 3 [11-09-2025(online)].pdf | 2025-09-11 |
| 17 | 202547030230-FORM 3 [03-10-2025(online)].pdf | 2025-10-03 |